IPP Bureau
Briefs: Dr. Reddy's Laboratories and Aurobindo Pharma
By IPP Bureau - August 06, 2023
The inspection closed with zero observations and a classification of No Action Indicated
Tatva Chintan Pharma Chem posts Q1 FY24 consolidated PAT at Rs. 9.50 Cr
By IPP Bureau - August 06, 2023
The company has reported total income of Rs. 115.37 crores during the period ended June 30, 2023
Eugia Pharma receives USFDA approval for Vancomycin Hydrochloride for Injection USP
By IPP Bureau - August 06, 2023
The product is being launched in August 2023
Fortis Healthcare Q1 FY24 consolidated PAT drops at Rs. 111.76 Cr
By IPP Bureau - August 06, 2023
Fortis Healthcare has reported total income of Rs. 1665.55 crores during the period ended June 30, 2023
Indraprastha Medical Corporation Q1 FY24 PAT up at Rs. 30.50 Cr
By IPP Bureau - August 06, 2023
The company has reported total income of Rs. 310.07 crores during the period ended June 30, 2023
USFDA approves Merck’s ERVEBO for use in children 12 months of age and older
By IPP Bureau - August 05, 2023
Merck continues progress in helping to protect people at risk of Zaire ebolavirus disease
Granules Pharmaceuticals successfully completes USFDA post marketing adverse drug experience inspection with zero observations
By IPP Bureau - August 05, 2023
The inspection was conducted at Granules Pharmaceuticals Inc. (GPI) from July 31, 2023 to August 03, 2023
Yashoda Medicity, Indirapuram and Draeger India join hands to establish modular ICU setup
By IPP Bureau - August 05, 2023
Aiming to establish a state-of-the-art healthcare facility in India that integrates the latest technologies, exceptional patient comfort, and optimal clinical outcomes
Biocon Biologics announces leadership appointments
By IPP Bureau - August 05, 2023
Zydus Wellness posts Q1 FY24 consolidated PAT at Rs. 110.4 Cr
By IPP Bureau - August 04, 2023
The company has reported total income of Rs. 704.5 crores during the period ended June 30, 2023
Dabur India posts Q1 FY24 PAT at Rs. 463.88 Cr
By IPP Bureau - August 04, 2023
The company has posted net profit of Rs. 463.88 crores for the period ended June 30, 2023
Lupin posts Q1 FY24 consolidated PAT at Rs. 452.26 Cr
By IPP Bureau - August 04, 2023
The company has reported total income of Rs. 4836.89 crores during the period ended June 30, 2023
Piramal Pharma posts Q1 FY24 consolidated loss at Rs. 98.58 Cr
By IPP Bureau - August 04, 2023
The company has reported total income of Rs. 1787.16 crores during the period ended June 30, 2023
Sartorius Bioreactors integrate Emerson Technology to speed new therapies to market
By IPP Bureau - August 04, 2023
DeltaV control system natively integrated into Sartorius Biostat STR bioreactors provide a foundation for semi-autonomous operations and up to 80% less integration time
Supriya Lifescience collaborates with Plasma Nutrition for protein technology
By IPP Bureau - August 03, 2023
The primary purpose of this collaboration is to bring the optimized protein into the Indian market
